Emeis

International portfolio optimisation to be continued

01/10/19 -"Orpea released satisfying H1 19 results, reconfirmed its FY goals and claims to continue broadening its international real estate portfolio. "

PDF page sample
Pages
53
Language
English
Published on
01/10/19
Download
You may also be interested by these reports :
30/10/26
Amplifon’s Q3 sales met expectations, while adjusted EBITDA missed. All regions recorded growth. Profitability improved, but full-year guidance ...
29/10/26
Clariane’s Q3 confirmed the operating turnaround: organic growth accelerated to 4.9%, occupancy reached 93% and France finally joined the party. The ...
28/10/26
The change in our NAV calculation reflects a change of analyst covering the stock. Our NAV/SOTP valuation is now based on a new breakdown separating ...
27/10/26
Despite some near-term caution (discussed in the EPS section), we continue to see sizeable upside for bioMerieux, supported by its dominance in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO